Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
about
Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasiaHuman papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesionsPathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapiesClinical significance of human papillomavirus genotypingFertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysisVaginal self-sampling is a cost-effective way to increase participation in a cervical cancer screening programme: a randomised trialCross-sectional study of genital carcinogenic HPV infections in Paramaribo, Suriname: prevalence and determinants in an ethnically diverse population of women in a pre-vaccination era.Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test.The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis.The clinical implementation of primary HPV screening.Eurogin 2016 Roadmap: how HPV knowledge is changing screening practice.Immediate referral to colposcopy versus cytological surveillance for low-grade cervical cytological abnormalities in the absence of HPV test: A systematic review and a meta-analysis of the literature.Quality assurance of human papillomavirus (HPV) testing in the implementation of HPV primary screening in Norway: an inter-laboratory reproducibility study.Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.Metaprop: a Stata command to perform meta-analysis of binomial dataANOVA model for network meta-analysis of diagnostic test accuracy data.Functional foods and their role in cancer prevention and health promotion: a comprehensive review.Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study.Increased methylation of human papillomavirus type 16 DNA is associated with the severity of cervical lesions in infected females from northeast China.Comprehensive control of human papillomavirus infections and related diseasesAnalysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study.Comparing the Cervista HPV HR test and Hybrid Capture 2 assay in a Dutch screening population: improved specificity of the Cervista HPV HR test by changing the cut-off.Protecting the underscreened women in developed countries: the value of HPV testWomen's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening programA population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off.Annual Papanicolaou screening for 5 years among human papillomavirus-negative womenHuman papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, HaitiClinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.Human papillomavirus type-specific prevalence in the cervical cancer screening population of Czech women.Self-sampling to increase participation in cervical cancer screening: an RCT comparing home mailing, distribution in pharmacies, and recall letter.Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study.Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology.Population-level scale-up of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in ZambiaPresence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological AbnormalitiesThe end of the decline in cervical cancer mortality in Spain: trends across the period 1981-2012.The implementation of an organised cervical screening programme in Poland: an analysis of the adherence to European guidelines.Systematic review of model-based cervical screening evaluations.Screening of cervical cancer in Catalonia 2006-2012.Barriers to and facilitators of compliance with clinic-based cervical cancer screening: population-based cohort study of women aged 23-60 years
P2860
Q24186960-E996F1D6-1844-4D63-84C2-D419F84F797FQ24198236-F66BA0AE-DC57-4435-B4EB-013975221449Q26744446-4A33AABC-FA39-499D-8B5F-FCE4B0EDA236Q26771981-C5B0AF3F-5FAE-4B0F-AA86-3E966CDC597AQ28250529-FD819B17-B0C1-4270-9174-69B288B11F24Q28650225-156DEF9F-518A-4BC3-9402-31C6C74A6E10Q29353702-38DDAA11-4735-47E4-B304-9515014C7D11Q30238772-254079A7-DB1E-4F9E-A5CE-872FA9657237Q30238947-01EC3EC9-C900-4EE0-B76A-5710FED5A138Q30238954-4C252CF7-C812-43E1-AE2E-C9B8D8701594Q30239987-EEDF8A06-7DE9-4344-A548-42A1959F7CD2Q30245568-3346E72E-7B29-4A81-A36A-A0AD29F9F282Q30829696-D43E1517-F62D-4850-BD20-31D79658846CQ30863996-3E3CF1E4-0205-469B-A10F-FB8D3E9F952BQ30916914-DD7B80F9-13EA-41DD-964E-35242588EF40Q31132331-4BA53854-5835-4176-AFE3-E2705A6AD3E5Q33622636-3171EFDF-E3BA-42BE-AAEF-F538EC2880D3Q33647348-2EF95A83-60F2-4723-B209-866B9CC67969Q33684676-830701D3-707A-44C0-A03F-203E4F26BD7DQ33772648-7BBE2F03-2740-4069-A083-A2868377461CQ33930720-57583E49-8BEC-4DB0-8142-7500ACDB4F66Q33933176-F4CAB9F9-3C0F-4A79-9178-BBA067C45642Q34062696-17684C01-9C40-4D7E-9B7C-0D6F95D587D9Q34374999-7161317B-8C71-469E-939C-CB84D2F82D66Q34789131-70001141-8422-4E60-9B61-0286D3469CF3Q34929075-F0477461-EC49-4FC0-9A92-355F29963C05Q35009255-3DC1E202-ABF8-47F5-8BEC-1CD4724E183BQ35036033-5043B84B-C8E8-4A6A-8354-C8E0A965D6C9Q35050431-F7A375F2-56C6-4E89-90C0-0E7D9C9F6A87Q35098354-34B54607-B3B3-4CD3-B929-80237669A037Q35108590-E315D171-13D3-461A-8EDF-5EA855A3FE48Q35117225-C1F36DF7-07A0-4162-BB84-4B5FEF6361A7Q35203306-0C017870-2C7C-4AD0-8938-DF27EEC8A893Q35464552-765521E9-48EA-4F10-A5AD-00E017D4F463Q35498040-12992C70-8717-494B-90BF-0C9680701A5AQ35534341-499CA9E1-CE67-4E1D-96C8-0D0CA053B16FQ35563325-19B40449-02A9-45B7-ADF8-1BDDB92A817DQ35568922-911E0D6A-A351-4C97-BED4-2AB591F0E9F3Q35605626-3ED077EA-B02B-4DC2-B931-46AE2483D36EQ35641828-A75FDD6B-6790-4FB3-9B47-344C95E7E8C4
P2860
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evidence regarding human papil ...... prevention of cervical cancer.
@en
type
label
Evidence regarding human papil ...... prevention of cervical cancer.
@en
prefLabel
Evidence regarding human papil ...... prevention of cervical cancer.
@en
P2093
P1433
P1476
Evidence regarding human papil ...... prevention of cervical cancer.
@en
P2093
Ahti Anttila
Chris J L M Meijer
George Koliopoulos
Guglielmo Ronco
Marc Arbyn
Mario Poljak
Pontus Naucler
Rengaswamy Sankaranarayanan
P304
P356
10.1016/J.VACCINE.2012.06.095
P407
P478
30 Suppl 5
P577
2012-11-01T00:00:00Z